Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
3.285
-0.045 (-1.35%)
Jul 21, 2025, 11:25 AM - Market open

Jasper Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
21.2920.4217.0816.5711.414.8
Upgrade
Research & Development
61.6855.8251.7934.6325.4215.88
Upgrade
Operating Expenses
82.9776.2468.8651.236.8320.68
Upgrade
Operating Income
-82.97-76.24-68.86-51.2-36.83-20.68
Upgrade
Interest & Investment Income
4.35.065.20.7--
Upgrade
Other Non Operating Income (Expenses)
-0.11-0.09-0.827.09-3.08-10.99
Upgrade
EBT Excluding Unusual Items
-78.78-71.27-64.48-43.41-39.91-31.67
Upgrade
Other Unusual Items
--0.025.739.28-
Upgrade
Pretax Income
-78.78-71.27-64.47-37.69-30.64-31.67
Upgrade
Net Income
-78.78-71.27-64.47-37.69-30.64-31.67
Upgrade
Net Income to Common
-78.78-71.27-64.47-37.69-30.64-31.67
Upgrade
Shares Outstanding (Basic)
151510410
Upgrade
Shares Outstanding (Diluted)
151510410
Upgrade
Shares Change (YoY)
29.64%39.72%186.15%220.19%558.67%-
Upgrade
EPS (Basic)
-5.25-4.89-6.18-10.33-26.89-183.08
Upgrade
EPS (Diluted)
-5.25-4.89-6.18-10.33-26.89-183.08
Upgrade
Free Cash Flow
-70.24-63.15-52.33-46.43-36.11-18.27
Upgrade
Free Cash Flow Per Share
-4.68-4.33-5.01-12.73-31.69-105.60
Upgrade
EBITDA
-81.61-74.87-67.75-50.22-36.46-
Upgrade
D&A For EBITDA
1.361.371.110.980.38-
Upgrade
EBIT
-82.97-76.24-68.86-51.2-36.83-20.68
Upgrade
Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q